Fuzuloparib and Apatinib Combination Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer
Groundbreaking Study Results
A groundbreaking phase 3 study presented at the prestigious ESMO Virtual Plenary Session has revealed promising results regarding the combination of fuzuloparib and apatinib in treating HER2-negative metastatic breast cancer patients carrying germline BRCA1/2 mutations.
Substantial PFS Improvement
The study found that fuzuloparib plus apatinib significantly improved progression-free survival (PFS) compared to standard chemotherapy. Patients receiving the combination therapy experienced a remarkable 73% reduction in the risk of disease progression or death, with a median PFS of 11.0 months versus just 3.0 months with chemotherapy.
Single-Agent Fuzuloparib Also Effective
Impressively, single-agent fuzuloparib also yielded a significant improvement in PFS compared to chemotherapy, with a median PFS of 6.7 months. This represents a 51% reduction in the risk of disease progression or death.
Safety and Tolerability Profile
In terms of safety, the combination of fuzuloparib and apatinib was well-tolerated, with a profile consistent with previous studies on each drug. The most common grade 3 or higher adverse events included decreased white blood cell count, decreased neutrophil count, and hypertension.
Expert Insights
Dr. Huiping Li, the lead researcher of the study, stated, “Our findings support the use of fuzuloparib plus apatinib or fuzuloparib alone for HER2-negative metastatic breast cancer patients with a germline BRCA mutation.”
Significance for Patients
These promising results offer hope to patients with advanced breast cancer and germline BRCA1/2 mutations. The combination of fuzuloparib and apatinib or fuzuloparib alone could potentially become valuable treatment options, extending PFS and improving patient outcomes.
Ongoing Research and Future Implications
Further research is ongoing to investigate the long-term efficacy and safety of this combination therapy. However, the preliminary findings from this study hold significant implications for the treatment of breast cancer patients with BRCA mutations.
Mehek 
Divya